\
&
Contact us
\
&
Contact us
Published on | 3 weeks ago
Programmes Climate, Energy, Mobility EITThe EIT (european institute for innovation and technology) Urban Mobility's open call invites applications from various organizations, including startups, SMEs, academia, and public authorities to deliver specialized trainings. One of the primary tasks of the EIT is notably to educate the people involved in new innovations and policies.
This Urban Mobility Explained (UMX) Open Call focuses on a series of specific activity areas aimed at enhancing the skills and capabilities of mobility professionals and organisations, particularly at the local/city level, to achieve systemic transformations for more liveable cities.
👥 Budget
The total budget for this call is between 2 and 4 million EUR and the maximum budget per proposal is 700.000 EUR. The call is also open to mono-participant applicant but special rules then apply as is the case for partners from Hungary and Switzerland.
🎬 Call to action
You can apply up to the 30th of september and there is a preparatory webinar on the 15th of July. You can find all the details here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
